An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis

Nephrology Dialysis Transplantation

Volumn 26, Issue 8, 2011, Pages 2526-2532

  Hoxha, Elion ^a   Harendza, Sigrid ^a   Zahner, Gunter ^a   Panzer, Ulf ^a   Steinmetz, Oliver ^a   Fechner, Kai ^b   Helmchen, Udo ^c   Stahl, Rolf A K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Institute of Experimental Immunology   (Germany)

^c Nierenregister Hamburg   (Germany)

Author keywords

membranous glomerulonephritis; nephrotic syndrome; PLA 2R antibodies; rituximab

Indexed keywords

PHOSPHOLIPASE A2 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CELL STRAIN HEK293; CHILD; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; KIDNEY BIOPSY; KIDNEY INJURY; MAJOR CLINICAL STUDY; MEMBRANOUS GLOMERULONEPHRITIS; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; PROTEINURIA; SINGLE DRUG DOSE;

ANTIBODIES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; FLUORESCENT ANTIBODY TECHNIQUE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOBLOTTING; KIDNEY GLOMERULUS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PROTEINURIA; RECEPTORS, PHOSPHOLIPASE A2;

EID: 79961085790     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr247     Document Type: Article

References (12)

1. Cattran D. Management of membranous nephropathy: when and what for treatment? J Am Soc Nephrol 2005;16:1188-1194 (Pubitemid 41716503)
2. Polanco N, Gutiérrez E, Covarśi A et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010;21:697-704
3. Beck LH, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361:11-21
4. Stahl R A K, Hoxha E, Fechner K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med 2010;363:496-498
5. Cravedi P, Ruggenenti P, Sghirlanzoni MC et al. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007;2:932-937
6. Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 2011;364:689-690
7. Burstein DM, Korbet SM, Schwartz MM. Membranous glomerulonephritis and malignancy. Am J Kidney Dis 1993;22:5-10 (Pubitemid 23203492)
8. Segarra A, Praga M, Ramos N et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitordependent patients. Clin J Am Soc Nephrol 2009;4:1083-1088
9. Fervenza FC, Abraham RS, Erickson SB et al. Mayo Nephrology Collaborative Group. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2010;5:2188-2198
10. Huang H, Benoist C, Mathis D. Rituximab specifically depletes shortlived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci U S A 2010;107:4658-4663
11. Beck LH, Hofstra JM, Beck DM et al. Anti-PLA2R Antibodies Correlate with Clinical Status in Idiopathic Membranous Nephropathy. San Diego, CA: ASN Renal Week, 2009
12. Beck LH, Salant DJ. Membranous nephropathy: recent travels and new roads ahead. Kidney Int 2010;77:765-770